[The JUPITER trial: a new approach in primary prevention]

Area of Science:

• Cardiology
• Preventive Medicine
• Biomarkers

Context:

• Current guidelines for cardiovascular disease primary prevention rely on global risk estimation using factors like age, sex, lipids, and blood pressure.
• Target LDL-cholesterol levels are stratified as <100 mg/dL (high-risk), <130 mg/dL (intermediate-risk), and <160 mg/dL (low-risk).
• High-sensitivity C-reactive protein (hs-CRP) is an emerging independent cardiovascular risk marker.

Purpose:

• To review the findings and implications of the JUPITER trial regarding cardiovascular disease primary prevention.
• To discuss the impact of hs-CRP levels on cardiovascular risk stratification.
• To evaluate the effectiveness of current primary prevention guidelines in light of new evidence.

Summary:

• The JUPITER trial investigated rosuvastatin's efficacy in patients with LDL-cholesterol <130 mg/dL and hs-CRP ≥2 mg/L.
• Rosuvastatin significantly reduced cardiovascular mortality and all-cause mortality in this low- to intermediate-risk group.
• These results contrast with current guidelines that do not typically recommend statin therapy for such individuals.

Impact:

• The JUPITER trial findings challenge existing primary prevention strategies based solely on traditional risk factors.
• Elevated hs-CRP may identify individuals who benefit from statin therapy despite having normal LDL-cholesterol levels.
• This review explores the potential shift in clinical practice and guideline recommendations for cardiovascular risk management.